JP2018512397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512397A5 JP2018512397A5 JP2017547001A JP2017547001A JP2018512397A5 JP 2018512397 A5 JP2018512397 A5 JP 2018512397A5 JP 2017547001 A JP2017547001 A JP 2017547001A JP 2017547001 A JP2017547001 A JP 2017547001A JP 2018512397 A5 JP2018512397 A5 JP 2018512397A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- agonist
- administering
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 65
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 42
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 42
- 239000000556 agonist Substances 0.000 claims description 38
- 238000002512 chemotherapy Methods 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 230000005855 radiation Effects 0.000 claims description 26
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 230000004069 differentiation Effects 0.000 claims description 12
- 210000002540 macrophage Anatomy 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 238000001959 radiotherapy Methods 0.000 claims description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 5
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 229950007217 tremelimumab Drugs 0.000 claims description 4
- 230000004614 tumor growth Effects 0.000 claims description 3
- 102000004452 Arginase Human genes 0.000 claims description 2
- 108700024123 Arginases Proteins 0.000 claims description 2
- 238000009175 antibody therapy Methods 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562131562P | 2015-03-11 | 2015-03-11 | |
| US62/131,562 | 2015-03-11 | ||
| PCT/US2016/021486 WO2016145030A1 (en) | 2015-03-11 | 2016-03-09 | Compositions and methods for enhancing the efficacy of cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018512397A JP2018512397A (ja) | 2018-05-17 |
| JP2018512397A5 true JP2018512397A5 (enExample) | 2019-04-18 |
Family
ID=56880519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547001A Pending JP2018512397A (ja) | 2015-03-11 | 2016-03-09 | 癌治療の有効性を高めるための組成物及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180044428A1 (enExample) |
| EP (1) | EP3268387A4 (enExample) |
| JP (1) | JP2018512397A (enExample) |
| KR (1) | KR20180002597A (enExample) |
| CN (1) | CN107531773A (enExample) |
| AU (1) | AU2016229810A1 (enExample) |
| CA (1) | CA2978318A1 (enExample) |
| HK (1) | HK1247630A1 (enExample) |
| IL (1) | IL254103A0 (enExample) |
| RU (1) | RU2017134104A (enExample) |
| SG (1) | SG11201706958SA (enExample) |
| WO (1) | WO2016145030A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| EP3331917A1 (en) * | 2015-08-04 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| EP3582855A1 (en) * | 2017-02-15 | 2019-12-25 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
| CA3095134A1 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in dna isolated from exosomes |
| CN113412130A (zh) * | 2018-12-08 | 2021-09-17 | 得克萨斯州大学系统董事会 | 用于诊断和治疗癌症及其他疾病的对促肿瘤癌症相关成纤维细胞的识别和靶向 |
| CN112007149A (zh) * | 2019-05-29 | 2020-12-01 | 思格(苏州)生物科技有限公司 | 一种新型复合免疫佐剂及其应用 |
| WO2021062332A1 (en) * | 2019-09-27 | 2021-04-01 | Icahn School Of Medicine At Mount Sinai | Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer |
| WO2021098851A1 (en) * | 2019-11-20 | 2021-05-27 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ctla4/ox40 bispecific antibodies and uses thereof |
| WO2021098750A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists |
| JP7702954B2 (ja) * | 2019-12-27 | 2025-07-04 | ハイファイバイオ， インコーポレイテッド | 抗ｏｘ４０抗体およびその使用 |
| US20230183366A1 (en) * | 2020-05-13 | 2023-06-15 | Inserm (Institut National De La Santé Et De La Recherch Médicale) | Recombinant proteins with ox40 activating properties |
| US12595307B2 (en) | 2020-06-11 | 2026-04-07 | Nantbio, Inc. | Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors |
| EP4448111A4 (en) * | 2021-12-15 | 2026-03-18 | Univ Texas | METHODS AND COMPOSITIONS FOR MODIFYING A TUMOR MICROBIOME |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2646626A1 (en) * | 2006-03-22 | 2007-09-27 | Apogenix Gmbh | Antibody specific for human il-4 for the treatment of cancer |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| KR20100014588A (ko) * | 2007-02-27 | 2010-02-10 | 제넨테크, 인크. | 길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도 |
| WO2010014784A2 (en) * | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| PT2769737T (pt) * | 2009-07-20 | 2017-06-29 | Bristol Myers Squibb Co | Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas |
| US20130064831A1 (en) * | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| AU2013216320A1 (en) * | 2012-02-01 | 2014-04-03 | Compugen Ltd. | C10RF32 antibodies, and uses thereof for treatment of cancer |
| WO2017134292A1 (en) * | 2016-02-04 | 2017-08-10 | Glenmark Pharmaceuticals S.A. | Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis |
-
2016
- 2016-03-09 CN CN201680014559.7A patent/CN107531773A/zh active Pending
- 2016-03-09 US US15/556,864 patent/US20180044428A1/en not_active Abandoned
- 2016-03-09 SG SG11201706958SA patent/SG11201706958SA/en unknown
- 2016-03-09 JP JP2017547001A patent/JP2018512397A/ja active Pending
- 2016-03-09 WO PCT/US2016/021486 patent/WO2016145030A1/en not_active Ceased
- 2016-03-09 KR KR1020177025629A patent/KR20180002597A/ko not_active Withdrawn
- 2016-03-09 HK HK18107203.8A patent/HK1247630A1/zh unknown
- 2016-03-09 CA CA2978318A patent/CA2978318A1/en not_active Abandoned
- 2016-03-09 RU RU2017134104A patent/RU2017134104A/ru not_active Application Discontinuation
- 2016-03-09 AU AU2016229810A patent/AU2016229810A1/en not_active Abandoned
- 2016-03-09 EP EP16762392.5A patent/EP3268387A4/en not_active Withdrawn
-
2017
- 2017-08-22 IL IL254103A patent/IL254103A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7797549B2 (ja) | ヒトメソテリンキメラ抗原受容体およびその使用 | |
| Kim et al. | A phase II study of avelumab monotherapy in patients with mismatch repair–deficient/microsatellite instability–high or POLE-mutated metastatic or unresectable colorectal cancer | |
| Ruan et al. | Immunogenic cell death in colon cancer prevention and therapy | |
| Neoptolemos et al. | Therapeutic developments in pancreatic cancer: current and future perspectives | |
| JP2022543555A (ja) | ｍｉＲＮＡ－１９３ａに関する新たな処置 | |
| US20230135171A1 (en) | Methods and systems for molecular disease assessment via analysis of circulating tumor dna | |
| Tarhini et al. | Neoadjuvant immunotherapy of locoregionally advanced solid tumors | |
| TWI895295B (zh) | 偵測編碼新生抗原之融合基因之方法 | |
| WO2021136933A1 (en) | Immunotherapeutic treatment of cancer | |
| Kim et al. | Strategies to overcome hurdles in cancer immunotherapy | |
| Pietrantonio et al. | Systemic treatment of patients with gastrointestinal cancers during the COVID-19 outbreak: COVID-19-adapted recommendations of the National Cancer Institute of Milan | |
| Yang et al. | Liver metastasis of colorectal cancer: Mechanism and clinical therapy | |
| Zhou et al. | Tumour plasticity and tumour microenvironment interactions as potential immunologic targets for pancreatic cancer treatment | |
| WO2022096896A1 (en) | Mycobacterial immunotherapy for treating cancer | |
| CN118317778A (zh) | 工程化nk细胞及其用途 | |
| US20220265820A1 (en) | Tumor immunotherapy using sindbis viral vectors and agonist monoclonal antibodies | |
| Iveson et al. | 6504 ORAL safety and efficacy of epirubicin, cisplatin, and capecitabine (ECX) plus rilotumumab (R) as first-line treatment for unresectable locally advanced (LA) or metastatic (M) gastric or esophagogastric junction (EGJ) adenocarcinoma | |
| US20250114354A1 (en) | Combination treatment regimens - smarca2 degrader with pd-1 inhibitors | |
| Xia et al. | Immunotherapy resistance in malignant pleural mesothelioma: Mechanistic foundations, clinical evidence, and precision therapeutic strategies | |
| Zhao et al. | 659 Repeated dosing of anti-Claudin 18.2 CAR-T in metastatic gastrointestinal cancer | |
| Tavakoli et al. | Personalized immunotherapy in HCC: synthesis, delivery, and clinical progress of mRNA-based vaccines | |
| Brito | Cancer Immunotherapy: Current Landscape and Future Directions | |
| US20230405059A1 (en) | A mycobacterium for use in cancer therapy | |
| Sikdar et al. | Microbiome-derived hydroxyphenyl propanoates enhance antitumour immunity by potentiating gasdermin D activity in tumour-associated myeloid cells | |
| Yi¹ et al. | and classification in discriminating |